Progesterone
Requirements/Sources
Therapeutic Dosages
Therapeutic Uses
What Is the Scientific Evidence for Progesterone?
Osteoporosis
Menopausal Symptoms
Opposing Estrogen
Safety Issues
References
1 Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol . 1999;94:225-228.
2 Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response [letter]. Lancet . 1999;354:1447-1448.
3 Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women [letter]. Lancet . 1998;351:1255-1256.
4 Lee JR. Is natural progesterone the missing link in osteoporosis prevention and treatment? Med Hypotheses . 1991;35:316-318.
5 Lee JR. Osteoporosis reversal with transdermal progesterone. Lancet . 1990;336:1327.
6 Lee JR. Osteoporosis reversal, the role of progesterone. Int Clin Nutr Rev . 1990;10:384-391.
7 Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol . 1999;94:225-228.
8 Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, et al. Soymilk or progesterone for prevention of bone loss: a 2 year randomized, placebo-controlled trial. Eur J Nutr . 2004 Apr 14. [Epub ahead of print]
9 Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol . 1999;94:225-228.
10 Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev . 1990;11:386-398.
11 Verhaar HJ, Damen CA, Duursma SA, et al. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone . 1994;15:307-311.
12 Lee JR. Is natural progesterone the missing link in osteoporosis prevention and treatment? Med Hypotheses . 1991;35:316-318.
13 Lee JR. Osteoporosis reversal with transdermal progesterone. Lancet . 1990;336:1327.
14 Lee JR. Osteoporosis reversal, the role of progesterone. Int Clin Nutr Rev . 1990;10:384-391.
15 Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol . 1999;94:225-228.
16 Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol . 1999;94:225-228.
17 Arky R. Physicians' Desk Reference . 53rd ed. Montvale, NJ: Medical Economics; 1999:125.
18 Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response [letter]. Lancet . 1999;354:1447-1448.
19 Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone from Progest cream in postmenopausal women [letter]. Lancet . 1998;351:1255-1256.
20 Wren BG, Champion SM, Willetts K, et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause . 2003;10:13-18.
21 Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril . 2003;79:221-222.
22 Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol . 1999;180(6 Pt 1):1504-1511.
23 Hermann AC, Nafziger AN, Victory J, et al. Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administrationapproved oral progesterone product. J Clin Pharmacol . 2005;45(6):614-619
Revision Information
- Reviewer: EBSCO CAM Review Board
- Review Date: 07/2012 -
- Update Date: 07/25/2012 -

